Recent News

• 11.02.2026 - Assembly Biosciences to Participate in Upcoming Investor Conferences
• 10.29.2026 - Assembly Biosciences Doses First Two Participants in Phase 2 Study of Oral NTCP Inhibitor ABI-6250 for Chronic Hepatitis Delta Virus
• 10.05.2026 - Assembly Biosciences to Present Positive Phase 1a Safety, Tolerability and Target Engagement Data for ABI-6250 at AASLD The Liver Meeting® 2026
• 09.10.2026 - Assembly Biosciences to Present at the H.C. Wainwright & Co. 28th Annual Global Investment Conference
• 09.08.2026 - Assembly Biosciences Exercises U.S. Profit-Share Option with Gilead for HSV Helicase-Primase Inhibitor Program
• 08.13.2026 - Assembly Biosciences Reports Second Quarter 2026 Financial Results and Recent Updates
• 05.28.2026 - Assembly Biosciences Announces Upcoming Investor Conference Presentations
• 05.26.2026 - Assembly Biosciences Announces the Closing of its Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
• 05.22.2026 - Assembly Biosciences Announces Pricing of $100 Million Offering of Common Stock and Pre-Funded Warrants
• 05.22.2026 - Assembly Biosciences Announces Expansion of ABI-6250 Clinical Development Into Cholestatic Liver Diseases

Recent Filings

• 11.03.2026 - 4 Statement of changes in beneficial ownership of securities
• 11.03.2026 - 4 Statement of changes in beneficial ownership of securities
• 11.03.2026 - 4 Statement of changes in beneficial ownership of securities
• 11.03.2026 - 4 Statement of changes in beneficial ownership of securities
• 11.03.2026 - 4 Statement of changes in beneficial ownership of securities
• 11.02.2026 - 144 Report of proposed sale of securities
• 11.02.2026 - 144 Report of proposed sale of securities
• 11.02.2026 - 144 Report of proposed sale of securities
• 08.20.2026 - S-8 Securities to be offered to employees in employee benefit plans
• 08.14.2026 - 8-K/A Current report